Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026

Loading news article.

Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026 | WAPE

Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026

Article summary

Related companies

Comments —